News
Entera Bio Announces Publication Of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data I1n The Journal Of Bone And Mineral Research
8 Apr 24
Biotech, News, General
HC Wainwright & Co. Maintains Buy on Entera Bio, Maintains $10 Price Target
2 Apr 24
News, Price Target, Analyst Ratings
Entera Bio Announces Key Regulatory Milestone For Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling On Qualifying BMD As A Surrogate Endpoint For Osteoporosis Drugs is Expected Within 10 Months
26 Mar 24
Biotech, News, FDA, General
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
8 Mar 24
Earnings, News
Entera Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement
4 Mar 24
News
Press releases
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
8 Apr 24
Health Care, Press Releases
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
26 Mar 24
Biotech, Health Care, Press Releases, General
Thinking about buying stock in Entera Bio, Ocugen, Mind Medicine, MicroAlgo, or Flora Growth?
25 Mar 24
Opinion, Press Releases
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
8 Mar 24
Earnings, Press Releases